SCHNEIDER ELECTRIC 284.600 € (+10,83 %)
DSM FIRMENICH AG 93.100 € (+11,66 %)
AIR LIQUIDE 171.740 € (+0,15 %)
ASML HOLDING 1 440.000 € (+5,71 %)
SANOFI 72.770 € (-8,95 %)
PERNOD RICARD 67.880 € (-0,59 %)
PHILIPS KON 22.880 € (+0,35 %)
POSTNL 0.917 € (+0,71 %)
BENETEAU 6.020 € (+1,69 %)
ARCADIS 39.900 € (-5,00 %)
HERMES INTL 1 550.500 € (+2,78 %)
HEINEKEN 79.000 € (-1,27 %)
STMICROELECTRONICS 45.625 € (+6,36 %)
ASM INTERNATIONAL 788.600 € (+9,53 %)
KLARSEN 0.630 € (-12,26 %)
ATOS GROUP 31.200 € (-7,20 %)
SMCP 6.540 € (+5,40 %)
BNP PARIBAS ACT.A 108.840 € (+1,80 %)
RELX 31.400 € (-6,60 %)
WORLDLINE 9.970 € (-3,67 %)
TECHNIP ENERGIES 29.460 € (-9,69 %)
VIVENDI SE 1.982 € (-2,36 %)
SOITEC 104.450 € (+8,58 %)
BIC 67.600 € (+8,33 %)
ESSILORLUXOTTICA 163.600 € (-0,91 %)
IPSEN 157.200 € (-3,97 %)
TIKEHAU CAPITAL 15.660 € (-8,21 %)
INFOTEL 42.000 € (+1,20 %)
EUROAPI 0.979 € (-22,42 %)
ING GROEP N.V. 30.215 € (+5,10 %)
ADYEN 885.200 € (+0,48 %)
VALLOUREC 20.860 € (-1,60 %)
CVC CAPITAL 14.530 € (+0,83 %)
VOPAK 48.860 € (+4,67 %)
OPMOBILITY 13.070 € (+2,51 %)
ASSYSTEM 41.500 € (-3,94 %)
GL EVENTS 31.700 € (+1,93 %)
INTERPARFUMS 24.880 € (+2,13 %)
VALEO 14.980 € (+3,78 %)
SBM OFFSHORE 32.100 € (+1,26 %)
MONCEY (FIN.) NOM. 125.000 € (-2,34 %)
FORVIA 9.550 € (+3,33 %)
VIRBAC 341.500 € (-1,73 %)
OCI 4.046 € (+0,05 %)
2CRSI 26.580 € (+11,40 %)
CSG 16.514 € (-0,63 %)
SES 5.620 € (-16,86 %)
BUREAU VERITAS 27.910 € (-4,65 %)
AIRBUS 204.000 € (-2,81 %)
SAINT GOBAIN 76.040 € (+0,64 %)
VIRIDIEN 80.100 € (+0,56 %)
X-FAB 6.780 € (+7,11 %)
SAFRAN 340.300 € (+0,15 %)
BE SEMICONDUCTOR 197.500 € (+4,22 %)
ORANGE 17.075 € (-1,87 %)
RENAULT 27.970 € (+0,21 %)
AMUNDI 94.000 € (+6,40 %)
VEOLIA ENVIRON. 35.800 € (+1,85 %)
CREDIT AGRICOLE 18.785 € (+2,26 %)
KAUFMAN ET BROAD 25.450 € (+0,79 %) |
04/01/2023 13:30
AI/ML Innovations' Health Gauge to Investigate Potential Patent Infringement EnforcementTORONTO, ON / ACCESSWIRE / January 4, 2023 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, announces that its wholly owned subsidiary, Health Gauge Inc., is investigating the possibility of enforcement action regarding its patent rights for its personal health monitoring (smartwatch) & management solution. "The wearable health-tech market is worth multiple billions of dollars per year in the US alone," said Tim Daniels, Chairman of AI/ML Innovations. "It is our belief that there may be several notable industry participants who are currently infringing upon our patented technology. As a result, we are giving careful consideration to potential courses of action to defend our patented Intellectual Property and technology rights." As announced in a press release dated February 1, 2022, Health Gauge, has been granted a patent by the United States Patent and Trademark Office (US Patent No. 11183303), titled "Wearable Health Monitors and Methods of Monitoring Health" (the "Patent"). The Patent includes the use of multiple configurations of wearable health monitors, in conjunction with methods of analyzing bio-signals and monitoring health metrics for the purpose of assisting the user in achieving their personal health and wellness objectives by utilizing both behavioral and predictive analysis. In all, more than 65 claims were granted as a part of this Patent. Amongst other things, these claims detail: various wearable hardware specifications, configurations, combinations, and operations; data collection and analysis methods; and the application of Machine Learning software and/or algorithmic data and behavioral analysis software. ![]() About Health Gauge www.healthgauge.com Health Gauge's patented solution is a personal health monitoring & management system, which combines the latest wearable health monitors with sophisticated artificial intelligence software tools and proprietary cloud computing software, to help caregivers, patients, and healthcare professionals access and utilize relevant data, resulting in better recovery outcomes and healthy living objectives through the ability to make immediate and better health choices. ![]() About AI/ML Innovations Inc. https://aiml-innovations.com/ AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (100% owned by AIML), Tech2Heal (up to 22% ownership rights, with 9.44% currently owned), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB". On behalf of the Board of Directors For more information about AI/ML Innovations: Corporate video: https://www.youtube.com/watch?v=k2QSjo7clXc&feature=youtu.be Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. For AI/ML Innovations Investors Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at www.sedar.com. SOURCE: AI/ML Innovations Inc. View source version on accesswire.com: https://www.accesswire.com/733822/AIML-Innovations-Health-Gaugeto-Investigate-Potential-Patent-Infringement-Enforcement Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière

